Aerobic Training in Patients with Congenital Myopathy

Gitte Hedermann, Christoffer Rasmus Vissing, Karen Heje, Nicolai Preisler, Nanna Witting, John Vissing, Gitte Hedermann, Christoffer Rasmus Vissing, Karen Heje, Nicolai Preisler, Nanna Witting, John Vissing

Abstract

Introduction: Congenital myopathies (CM) often affect contractile proteins of the sarcomere, which could render patients susceptible to exercise-induced muscle damage. We investigated if exercise is safe and beneficial in patients with CM.

Methods: Patients exercised on a stationary bike for 30 minutes, three times weekly, for 10 weeks at 70% of their maximal oxygen uptake (VO2max). Creatine kinase (CK) was monitored as a marker of muscle damage. VO2max, functional tests, and questionnaires evaluated efficacy.

Results: Sixteen patients with CM were included in a controlled study. VO2max increased by 14% (range, 6-25%; 95% CI 7-20; p < 0.001) in the seven patients who completed training, and tended to decrease in a non-intervention group (n = 7; change -3.5%; range, -11-3%, p = 0.083). CK levels were normal and remained stable during training. Baseline Fatigue Severity Scale scores were high, 4.9 (SE 1.9), and tended to decrease (to 4.4 (SE 1.7); p = 0.08) with training. Nine patients dropped out of the training program. Fatigue was the major single reason.

Conclusions: Ten weeks of endurance training is safe and improves fitness in patients with congenital myopathies. The training did not cause sarcomeric injury, even though sarcomeric function is affected by the genetic abnormalities in most patients with CM. Severe fatigue, which characterizes patients with CM, is a limiting factor for initiating training in CM, but tends to improve in those who train.

Trial registration: The Regional Committee on Health Research Ethics of the Capital Region of Denmark H-2-2013-066 and ClinicalTrials.gov H2-2013-066.

Trial registration: ClinicalTrials.gov NCT02020187.

Conflict of interest statement

Competing Interests: NP reports received research support, honoraria, and travel funding from Genzyme Corporation. JV reports received research support, honoraria, and travel funding from Genzyme Corporation. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Fig 1. Flowchart, maximal oxygen uptake, workload…
Fig 1. Flowchart, maximal oxygen uptake, workload and plasma creatine kinase levels.
(A) 16 patients with CM were included in the study. Four patients from the 1st training group completed the training program. A non-intervention group of seven CM patients were tested twice, 10 weeks apart, before they participated in the training program (2nd training group). Only 3 patients from the non-intervention group completed the subsequent training program. In total, nine patients dropped out of the training program. (B) VO2max before and after 10 weeks of aerobic training in seven CM patients with an improvement corresponding to 215 ml O2 · min-1 (CI 121–308 ml O2 · min-1, * p = 0.001) (left bars). VO2max before and after 10 weeks of normal daily living in seven patients with CM (right bars). Black bars represent values before, and gray bars represent values after. The change seen in the intervention group was significant compared to the change in the non-intervention group (mixed Anova, p < 0.001). (C) Maximal workload before and after 10 weeks of aerobic training in seven CM patients who improved Wmax by 18 W (CI 11–24 W, ** p = < 0.001) (left bars). Wmax before and after 10 weeks of normal daily living in seven CM patients (right bars). Black bars represent values before, and gray bars represent values after. The change seen in the intervention group was significant compared to the change in the non-intervention group (mixed Anova, p < 0.001). (D) Dots represent plasma CK levels at week 0, 3 and 10 from the seven CM patients who finished the training program. All values are within the normal range or slightly elevated when corrected for age and gender. VO2max: maximal oxygen uptake; CM: congenital myopathy; Wmax: maximal workload; CK: creatine kinase.
Fig 2. Baseline muscle strength evaluated by…
Fig 2. Baseline muscle strength evaluated by MRC score in the seven patients who finished the training program (black bars) and in the nine patients who dropped out of the training program (gray bars).
A significant difference was found between the two groups in three muscle groups; ankle plantar flexion, * p

References

    1. Nance JR, Dowling JJ, Gibbs EM, Bönnemann CG. Congenital Myopathies: An Update. Curr Neurol Neurosci Rep 2012;12: 165–174. 10.1007/s11910-012-0255-x
    1. North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the diagnosis of congenital myopathies. Neuromuscul Disord 2014; 24: 97–116. 10.1016/j.nmd.2013.11.003
    1. Iannaccone ST, Castro D. Congenital Muscular Dystrophies and Congenital Myopathies. Contin Lifelong Learn Neurol 2013;19: 1509–1534.
    1. Werlauff U, Højberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Qual Life Res 2014;23: 1479–1488. 10.1007/s11136-013-0565-8
    1. Aitkens S, Kilmer DD, Wright NC, McCrory MA. Metabolic Syndrome in Neuromuscular Disease. Arch Phys Med Rehabil 2005;86: 1030–1036.
    1. Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurol 2005;64: 1064–1066.
    1. Ørngreen MC, Olsen DB, Vissing J. Aerobic training in patients with myotonic dystrophy type 1. Ann Neurol 2005;57: 754–757.
    1. Sveen ML, Jeppesen TD, Hauerslev S, Krag TO, Vissing J. Endurance training: An effective and safe treatment for patients with LGMD2I. Neurol 2007;68: 59–61.
    1. Sveen ML, Jeppesen TD, Hauerslev S, Køber L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain 2008;131: 2824–2831. 10.1093/brain/awn189
    1. Vissing CR, Preisler N, Husu E, Prahm KP, Vissing J. Aerobic training in patients with anoctamin 5 myopathy and hyperckemia. Muscle Nerve 2014;50: 119–123. 10.1002/mus.24112
    1. Voet N, Bleijenberg G, Hendriks J, de Groot I, Padberg G, van Engelen B, et al. Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD: an RCT. Neurology 2014;83: 1914–1922. 10.1212/WNL.0000000000001008
    1. Madsen KL, Hansen RS, Preisler N, Thøgersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function in Spinal Muscular Atrophy Type III. Muscle Nerve 2014;52: 240–244.
    1. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: A prospective study of healthy men and women. JAMA 1989;262: 2395–2401.
    1. Preisler N, Andersen G, Thogersen F, Crone C, Jeppesen TD, Wibrand F, et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurol 2009;72: 317–323.

Source: PubMed

3
Sottoscrivi